Research progress of cancer metabolism

Abstract

GUO Wen-Zheng-；Deng-Jiong. Research progress of cancer metabolism[J]. Journal of International Oncology, 2015, 42(4): 277-280.

［1］ Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation［J］. Cell, 2011, 144(5): 646674. ［2］ Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation［J］. Science, 2009, 324(5930): 10291033. ［3］ Jones RG, Thompson CB. Tumor suppressors and cell metabolism: a recipe for cancer growth［J］. Genes Dev, 2009, 23(5): 537548. ［4］ Ying H, Kimmelman AC, Lyssiotis CA, et al. Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism［J］. Cell, 2012, 149(3): 656670. ［5］ Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges andlimitations［J］. Nat Rev Cancer, 2009, 9(8): 550562 . ［6］ Dong C, Yuan T, Wu Y, et al. Loss of FBP1 by Snailmediated repression provides metabolic advantages in basallike breast cancer［J］. Cancer cell, 2013, 23(3): 316331. ［7］ Yang L, Xie M, Yang M, et al. PKM2 regulates the Warburg effect and promotes HMGB1 release in sepsis［J］. Nat Commun, 2014, 5:4436. ［8］ Yang W, Xia Y, Hawke D, et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis［J］. Cell, 2012, 150(4): 685696. ［9］ MartinezOutschoorn UE, Prisco M, Ertel A, et al. Ketones and lactate increase cancer cell "stemness," driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via MetaboloGenomics［J］. Cell cycle, 2011, 10(8): 12711286. ［10］ Riganti C, Gazzano E, Polimeni M, et al. The pentose phosphate pathway: an antioxidant defense and a crossroad in tumor cell fate［J］. Free Radic Bio Med, 2012, 53(3): 421436. ［11］ Hartmannsberger D, Mack B, Eggert C, et al. Transketolaselike protein 1 confers resistance to serum withdrawal in vitro［J］. Cancer Lett, 2011, 300(1): 2029. ［12］ Ren F, Wu H, Lei Y, et al. Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma［J］. Mol Cancer, 2010, 9: 81. ［13］ Hitosugi T, Zhou L, Elf S, et al. Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth［J］. Cancer cell, 2012, 22(5): 585600. ［14］ Galtieri A, Tellone E, Ficarra S, et al. Resveratrol treatment induces redox stress in red blood cells: a possible role of caspase 3 in metabolism and anion transport［J］. Bio Chem, 2010, 391(9): 10571065. ［15］ Pan S, World CJ, Kovacs CJ, et al. Glucose 6phosphate dehydrogenase is regulated through cSrcmediated tyrosine phosphorylation in endothelial cells［J］. Arterioscler Thromb Vasc Biol, 2009, 29(6): 895901. ［16］ Possemato R, Marks KM, Shaul YD, et al. Functional genomics reveal that the serine synthesis pathway is essential in breast cancer［J］. Nature, 2011, 476(7360): 346350. ［17］ Yamamoto T, Takano N, Ishiwata K, et al. Reduced methylation of PFKFB3 in cancer cells shunts glucose towards the pentose phosphate pathway［J］. Nat Commun, 2014, 5: 3480. ［18］ Yalcin A, Clem BF, ImbertFernandez Y, et al. 6Phosphofructo2kinase (PFKFB3) promotes cell cycle progression and suppresses apoptosis via Cdk1mediated phosphorylation of p27［J］. Cell Death Dis, 2014, 5:e1337. ［19］ Wallace DC. Mitochondria and cancer［J］. Nat Rev Cancer, 2012, 12(10): 685698. ［20］ Dang CV. Glutaminolysis: supplying carbon or nitrogen or both for cancer cells?［J］. Cell cycle, 2010, 9(19): 38843886. ［21］ Sandulache VC, Ow TJ, Pickering CR, et al. Glucose, not glutamine, is the dominant energy source required for proliferation and survival of head and neck squamous carcinoma cells［J］. Cancer, 2011, 117(13): 29262938. ［22］ Gao P, Tchernyshyov I, Chang TC, et al. cMyc suppression of miR23a/b enhances mitochondrial glutaminase expression and glutamine metabolism［J］. Nature, 2009, 458(7239): 762765. ［23］ Yuneva MO, Fan TW, Allen TD, et al. The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type［J］. Cell Metab, 2012, 15(2): 157170. ［24］ Santos CR, Schulze A. Lipid metabolism in cancer［J］. FEBS J, 2012, 279(15): 26102623. ［25］ Furuta E, Pai SK, Zhan R, et al. Fatty acid synthase gene is upregulated by hypoxia via activation of Akt and sterol regulatory element binding protein1［J］. Cancer Res, 2008, 68(4): 10031011. ［26］ Wang JB, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation［J］. Cancer cell, 2010, 18(3): 207219. ［27］ Israelsen WJ, Dayton TL, Davidson SM, et al. PKM2 isoformspecific deletion reveals a differential requirement for pyruvate kinase in tumor cells［J］. Cell, 2013, 155(2): 397409. ［28］ Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression［J］. Proc Natl Acad Sci USA, 2010, 107(5): 20372042.

[1]	Liu Na, Kou Jieli, Yang Feng, Liu Taotao, Li Danping, Han Junrui, Yang Lizhou.Clinical value of serum miR-106b-5p and miR-760 combined with low-dose spiral CT in the diagnosis of early lung cancer[J]. Journal of International Oncology, 2024, 51(6): 321-325.
[2]	Yang Mi, Bie Jun, Zhang Jiayong, Deng Jiaxiu, Tang Zuge, Lu Jun.Analysis of the efficacy and prognosis of neoadjuvant therapy for locally advanced resectable esophageal cancer[J]. Journal of International Oncology, 2024, 51(6): 332-337.
[3]	Yuan Jian, Huang Yanhua.Diagnostic value of Hp-IgG antibody combined with serum DKK1 and sB7-H3 in early gastric cancer[J]. Journal of International Oncology, 2024, 51(6): 338-343.
[4]	Chen Hongjian, Zhang Suqing.Study on the relationship between serum miR-24-3p， H2AFX and clinical pathological features and postoperative recurrence in liver cancer patients[J]. Journal of International Oncology, 2024, 51(6): 344-349.
[5]	Guo Zehao, Zhang Junwang.Role of PFDN and its subunits in tumorigenesis and tumor development[J]. Journal of International Oncology, 2024, 51(6): 350-353.
[6]	Zhang Baihong, Yue Hongyun.Advances in anti-tumor drugs with new mechanisms of action[J]. Journal of International Oncology, 2024, 51(6): 354-358.
[7]	Xu Fenglin, Wu Gang.Research progress of EBV in tumor immune microenvironment and immunotherapy of nasopharyngeal carcinoma[J]. Journal of International Oncology, 2024, 51(6): 359-363.
[8]	Wang Ying, Liu Nan, Guo Bing.Advances of antibody-drug conjugate in the therapy of metastatic breast cancer[J]. Journal of International Oncology, 2024, 51(6): 364-369.
[9]	Zhang Rui, Chu Yanliu.Research progress of colorectal cancer risk assessment models based on FIT and gut microbiota[J]. Journal of International Oncology, 2024, 51(6): 370-375.
[10]	Gao Fan, Wang Ping, Du Chao, Chu Yanliu.Research progress on intestinal flora and non-surgical treatment of the colorectal cancer[J]. Journal of International Oncology, 2024, 51(6): 376-381.
[11]	Liu Jing, Liu Qin, Huang Mei.Prognostic model construction of lung infection in patients with chemoradiotherapy for esophageal cancer based on SMOTE algorithm[J]. Journal of International Oncology, 2024, 51(5): 267-273.
[12]	Yang Lin, Lu Ning, Wen Hua, Zhang Mingxin, Zhu Lin.Study on the clinical relationship between inflammatory burden index and gastric cancer[J]. Journal of International Oncology, 2024, 51(5): 274-279.
[13]	Wang Junyi, Hong Kaibin, Ji Rongjia, Chen Dachao.Effect of cancer nodules on liver metastases after radical resection of colorectal cancer[J]. Journal of International Oncology, 2024, 51(5): 280-285.
[14]	Zhang Ningning, Yang Zhe, Tan Limei, Li Zhenning, Wang Di, Wei Yongzhi.Diagnostic value of cervical cell DNA ploidy analysis combined with B7-H4 and PKCδ for cervical cancer[J]. Journal of International Oncology, 2024, 51(5): 286-291.
[15]	Fu Yi, Ma Chenying, Zhang Lu, Zhou Juying.Research progress of habitat analysis in radiomics of malignant tumors[J]. Journal of International Oncology, 2024, 51(5): 292-297.

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles15

Recommended Articles

Metrics

Comments